Veterinary Antimicrobial Susceptibility Testing Global Market Report 2024

The global veterinary antimicrobial susceptibility testing market has grown strongly in recent years. It will grow from $34.78 billion in 2023 to $37.44 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The expansion observed in the historical period can be linked to several factors such as heightened environmental concerns, increasing demand for precision medicine, the adoption of a comprehensive 'one health' approach, rising consumer awareness, and the growth of companion animal healthcare.

The global veterinary antimicrobial susceptibility testing market is expected to see strong growth in the next few years. It will grow to $50.45 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth in the forecast period is driven by various factors including efforts to mitigate antibiotic resistance, compliance with regulatory requirements, the influence of global health events, and the increasing prevalence of pet ownership. Key trends expected in this period encompass the development of innovative solutions, a stronger focus on regulatory compliance, initiatives aimed at controlling zoonotic diseases, and the implementation of higher standards within the livestock industry.

The growth of the veterinary antimicrobial susceptibility testing market is anticipated to be propelled by the increasing prevalence of zoonotic diseases. Zoonotic diseases, which can be transmitted between different species, including from humans to animals, create a demand for testing to determine the most effective animal medication. Veterinary antimicrobial susceptibility testing plays a crucial role in selecting the optimal drug for treating bacterial infections in animals by considering treatment history and other factors. According to a July 2022 article published by the World Health Organization, there was a 64% increase in zoonotic cases in Africa. The global rise in zoonotic diseases, with 816 zoonotic pathogens out of 1407 human pathogens, emphasizes the need for effective veterinary antimicrobial susceptibility testing to address these emerging infectious diseases. This escalating prevalence of zoonotic diseases is a key driver for the growth of the veterinary antimicrobial susceptibility testing market.

The surge in pet ownership is another factor expected to drive the veterinary antimicrobial susceptibility testing market. Pet ownership involves caring for domesticated animals as companions or family members, and responsible pet owners prioritize the health and well-being of their animals. Veterinary antimicrobial susceptibility testing becomes crucial in ensuring the health of companion animals, as pet owners seek veterinary assistance when their pets show signs of illness or infection. With approximately 70% of households in the US owning pets in 2022, totaling around 90.5 million homes, according to an April 2022 article by Lemonade Inc., the increase in pet ownership contributes significantly to the demand for veterinary antimicrobial susceptibility testing. This trend reflects a growing focus on animal welfare and health.

Technological advancements represent a noteworthy trend in the veterinary antimicrobial susceptibility testing market. Major companies in the veterinary market are actively innovating new technologies to maintain their market positions. The use of advanced imaging techniques and algorithms for more accurate, reliable, and rapid veterinary antimicrobial susceptibility testing has gained prominence. In October 2021, Thermo Fisher Scientific and Q-linea introduced the ASTar System, a rapid antimicrobial susceptibility testing (rAST) system. This fully automated system employs imaging techniques and algorithms to monitor bacterial growth, eliminating the need for subculture and expediting the testing process. The adoption of such advanced technologies enhances the efficiency of veterinary antimicrobial susceptibility testing and contributes to the market's growth.

Prominent companies in the veterinary antimicrobial susceptibility testing market are actively introducing innovative products, particularly rapid tests, as part of their strategy to maintain a competitive edge. Rapid tests, also known as rapid diagnostic tests (RDTs) or rapid assays, are diagnostic procedures designed to provide quick results within a short timeframe. In March 2023, PDX Biotech LLC, a US-based biotechnology company, launched the OraStripdx, a rapid test capable of detecting active periodontal disease in dogs and cats within 10 seconds. The OraStripdx features an easy-to-use test strip that undergoes color changes based on the concentration of thiols in the patient’s oral fluid. Significantly, this test requires no anesthesia or sedation, providing a user-friendly approach to disease detection. The OraStripdx test strip plays a crucial role in detecting the development of disease that may not be directly visible, enabling pet owners and healthcare providers to identify diseases in their earliest stages. This rapid testing capability presents a major advantage in proactive disease management for pets.

In May 2022, bioMérieux, a France-based multinational biotechnology company, executed the acquisition of Specific Diagnostics for an undisclosed amount. This strategic move is anticipated to fortify bioMérieux's efforts against antimicrobial resistance, enhance its leading position in clinical microbiology, and further extend its global leadership in this field. Specific Diagnostics, a US-based company, specializes in the development of a rapid antimicrobial susceptibility testing (AST) system. This acquisition aligns with bioMérieux's commitment to addressing antimicrobial resistance challenges and expands its capabilities in clinical microbiology through the incorporation of Specific Diagnostics' rapid AST system into its product portfolio.

Major companies operating in the veterinary antimicrobial susceptibility testing market report are BioMérieux SA, Becton, Dickinson and Company, Bioguard Corporation, Bio-Rad Laboratories, Bruker Corporation, Condalab SA, FASTinov SA, Hardy Diagnostics Co., HiMedia Laboratories, Liofilchem Srl, Mast Group Ltd., Neogen Corporation, SSI Diagnostica A/S, Synbiosis, Thermo Fisher Scientific Inc., Accelerate Diagnostics Inc., Alifax S.r.l., Biogal Galed Labs Ltd., Cepheid Inc., Creative Diagnostics, Danaher Corporation, Eurofins Scientific SE, GenMark Diagnostics Inc., IDEXX Laboratories Inc., Luminex Corporation, Merck Co. & KGaA, Microbiologics Inc., Nanosphere Inc., QIAGEN N.V., R-Biopharm AG, T2 Biosystems Inc., Vetoquinol S.A., Virbac Inc., Zoetis Inc.

North America was the largest region in the veterinary antimicrobial susceptibility testing market in 2023. The regions covered in the veterinary antimicrobial susceptibility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary product categories within veterinary antimicrobial susceptibility testing comprise disks and plates, culture media, accessories and consumables, and automated AST (antimicrobial susceptibility test) instruments. Disks and plates, small circular filter paper pieces soaked in antibiotic solutions and dried, are utilized to determine the antibiotics to which an infectious organism is susceptible. This information allows healthcare professionals to administer the appropriate medication. This testing is conducted on both livestock and companion animals, carried out in veterinary reference laboratories, veterinary research institutes, and other related facilities.

This report provides veterinary antimicrobial susceptibility testing market statistics, including veterinary antimicrobial susceptibility testing industry global market size, regional shares, competitors with a veterinary antimicrobial susceptibility testing market share, detailed veterinary antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary antimicrobial susceptibility testing industry. This veterinary antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veterinary antimicrobial susceptibility testing market consists of revenues earned by entities by providing the disk diffusion technique and the broth dilution technique. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.